During August, there was a significant decline in the number of short positions held in Capricor Therapeutics, Inc. (NASDAQ: CAPR). As of August 15, there were 304,100 shares available for a short sale. This is a decline of 15.2% from the previous day’s total of 358,500 shares available for short sale. It is possible to derive the current short-interest ratio of 2.2 days by using the average daily trading volume of 136,800 shares as a starting point for the calculation. According to reports from other recent news, Director David B. Musket sold 28,215 shares of the company’s stock on June 29. This information was disclosed in another recent piece of news. The shares were acquired for a total cost of $106,370.55, which works out to a price of $3.77 per share on an average basis. The director now has 12,747 shares in the company, which have a value of $48,056.19, thanks to the successful transaction completion. Follow the link that was provided in the preceding sentence. You can access the transaction report presented to the Securities and Exchange Commission. Additionally, on Monday, June 27, Director David B. Musket sold 17,775 Capricor Therapeutics stock. There was the completion of this deal. There was a total of $78,921 worth of transactions involving the company’s shares, with each trade occurring at an average price of $4.44.
Following the successful conclusion of the transaction, the director was awarded direct ownership of 40,962 business shares, each of which has an estimated value of $181,871.28. In addition, on June 29 of this year, David B. Musket, currently a director at Capricor Therapeutics, sold 28,215 shares of the company’s stock. The shares were acquired for a total cost of $106,370.55, which works out to a price of $3.77 per share on an average basis. After the deal’s completion, the director now possesses 12,747 shares, each of which has a value of 48,056.19 dollars. Disclosures that are related to the sale might be found in this section of the website. 9.0 percent of the company’s shares are held in individual accounts by people who work for the company. Various institutional investors, including hedge funds and other investment companies, have recently bought and sold shares of the company’s stock. During the first three months of the year, Selective Wealth Management Inc. invested $732,000 in Capricor Therapeutics by purchasing stock. Compared to the previous quarter, Dimensional Fund Advisors LP made a 54.7% increase in the amount of money it invested in Capricor Therapeutics during the first quarter. Dimensional Fund Advisors LP has increased the value of its holdings by $510,000 after purchasing an additional 52,611 shares of stock in the biotechnology business since the beginning of the current quarter. This takes the total value of its holdings to $510,000. Capricor Therapeutics increased the proportion of ownership it owned in Capricor Group Inc. by 5.6% during the first three months of 2018.
The Vanguard Group Inc. now has 1,020,998 shares of the biotechnology company’s common stock, thanks to the addition of 54,260 new shares purchased throughout the quarter. The value of these shares on the market as of right now is $3,502,000. Charles Schwab Investment Management Inc. invested in the shares of Capricor Therapeutics with a total value of $51,000 during the first three months of the year. Last but not least, during the first quarter, State Street Corporation boosted the percentage of ownership it owned in Capricor Therapeutics by 10.4%. This was the highlight of the company’s performance. State Street Corp now has 79,224 shares of the biotechnology company’s stock, which has an estimated market value of $272,000 following the purchase of an additional 7,476 shares. To the tune of 9.49% of the total shares outstanding, institutional investors and hedge funds collectively hold a stake in the company. Bloomberg upgraded Capricor Therapeutics to a “sell” rating in a second piece of research published on the same day (Monday, May 23). When trading started on Tuesday, one share of Capricor Therapeutics was valued at $5.80 per unit. The firm’s market capitalization is currently sitting at $141.21 million, its price-to-earnings ratio stands at 5.58, and its beta value sits at 5.00. Over the previous year, the price of Capricor Therapeutics ranged from its all-time low of $2.56 to its all-time high of $5.99.
Over the previous 50 days, the company’s prices have moved to an average of $4.60, while over the previous 200 days, they have averaged $4.10. On August 10, a report detailing the performance of Capricor Therapeutics (NASDAQ: CAPR) was made available to the public. The biotechnology company reported that its earnings per share for the previous quarter came in at $0.29, which was $0.04 less than the consensus forecast of $0.25 among market analysts. The results for the same quarter in the current year, as compared to the performance for the same quarter in the previous year, resulted in a $0.21 decrease in earnings per share. Sell-side analysts anticipate that Capricor Therapeutics will generate a loss of 1.17 cents per share during the current financial year. Inc. The name of the company is Capricor Therapeutics. The clinical-stage biotechnology business, Capricor Therapies, Inc. (NASDAQ: CAPR), is committed to the discovery, development, and commercialization of first-in-class biological medicines to treat unusual disorders. Allogeneic cell therapy CAP-1002, which is Capricor’s primary candidate, is now being evaluated on people who have Duchenne muscular dystrophy to determine whether or not it has the potential to assist in the treatment of the illness.